Morse Asset Management Inc raised its stake in argenex SE (NASDAQ:ARGX – Free Report) by 69.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,282 shares of the company’s stock after acquiring an additional 934 shares during the quarter. Morse Asset Management Inc’s holdings in argenex were worth $2,188,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the stock. West Family Investments Inc. grew its position in shares of argenex by 17.6% in the third quarter. West Family Investments Inc. now owns 440 shares of the company’s stock valued at $422,000 after purchasing an additional 66 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in argenex by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,874 shares of the company’s stock worth $2,756,000 after purchasing an additional 58 shares during the last quarter. Harbour Investments Inc. lifted its holdings in argenex by 966.7% during the 3rd quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock worth $62,000 after purchasing an additional 58 shares during the last quarter. Optas LLC lifted its holdings in argenex by 4.6% during the 3rd quarter. Optas LLC now owns 250 shares of the company’s stock worth $240,000 after purchasing an additional 11 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in argenex by 19.7% in the 3rd quarter. Allworth Financial LP now owns 170 shares of the company’s stock valued at $158,000 after purchasing an additional 28 shares during the period. 60.32% of the stock is owned by institutional investors.
argenex Price Performance
Shares of NASDAQ:ARGX opened at $960.04 on Monday. The company’s 50 day moving average price is $923.87 and its two-hundred day moving average price is $860.78. argenex SE has a 12-month low of $661.85 and a 12-month high of $1,072.75. The firm has a market cap of $60.38 billion, a PE ratio of 33.50, a PEG ratio of 0.89 and a beta of 0.48.
argenex (NASDAQ:ARGX – Get Free Report) last announced its earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The company had revenue of $1.75 billion for the quarter. On average, research analysts expect that argenex SE will post 28.41 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on ARGX shares. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 21st. Morgan Stanley lowered their price objective on argenex from $1,190.00 to $1,130.00 and set an “overweight” rating on the stock in a research report on Friday. Barclays reissued a “buy” rating on shares of argenex in a report on Monday, September 7th. Wells Fargo & Company dropped their target price on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a report on Friday, October 23rd. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of argenex in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,155.24.
About argenex
argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.
Recommended Stories
- Five stocks we like better than argenex
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
